Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine

AK Dutta, JB Alberge, R Sklavenitis-Pistofidis… - Nature Reviews …, 2022 - nature.com
Multiple myeloma (MM) is a haematological malignancy of plasma cells characterized by
substantial intraclonal genetic heterogeneity. Although therapeutic advances made in the …

CD38 antibodies in multiple myeloma: back to the future

NWCJ Van de Donk, PG Richardson… - Blood, The Journal of …, 2018 - ashpublications.org
CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively
low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic …

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

P Moreau, MA Dimopoulos, J Mikhael, K Yong… - The Lancet, 2021 - thelancet.com
Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with
pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory …

CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade

L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li… - Cancer discovery, 2018 - AACR
Although treatment with immune checkpoint inhibitors provides promising benefit for patients
with cancer, optimal use is encumbered by high resistance rates and requires a thorough …

[HTML][HTML] The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases

KA Hogan, CCS Chini, EN Chini - Frontiers in immunology, 2019 - frontiersin.org
CD38 (Cluster of Differentiation 38) is a multifunctional ecto-enzyme that metabolizes NAD+
and mediates nicotinamide dinucleotide (NAD+) and extracellular nucleotide homeostasis …

[HTML][HTML] CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance

NWCJ Van de Donk, SZ Usmani - Frontiers in immunology, 2018 - frontiersin.org
MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression …

[HTML][HTML] Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy

SF Cho, KC Anderson, YT Tai - Frontiers in immunology, 2018 - frontiersin.org
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma

O Zavidij, NJ Haradhvala, TH Mouhieddine… - Nature cancer, 2020 - nature.com
Precursor states of multiple myeloma (MM) and its native tumor microenvironment need in-
depth molecular characterization to better stratify and treat patients at risk. Using single-cell …

[HTML][HTML] CD38: a target for immunotherapeutic approaches in multiple myeloma

F Morandi, AL Horenstein, F Costa, N Giuliani… - Frontiers in …, 2018 - frontiersin.org
Multiple Myeloma (MM) is a hematological cancer characterized by proliferation of malignant
plasma cells in the bone marrow (BM). MM represents the second most frequent …

[HTML][HTML] Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

E Terpos, M Engelhardt, G Cook, F Gay, MV Mateos… - Leukemia, 2020 - nature.com
Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-
19 infection and associated complications due to their immunocompromised state, the older …